ALGORAE PHARMACEUTICALS LIMITED - Announcements

16.7%

0.7¢

Market Cap $10.12M

Healthcare Biotechnology

Algorae Pharmaceuticals Limited is an Australia-based artificial-intelligence (AI)... Algorae Pharmaceuticals Limited is an Australia-based artificial-intelligence (AI) enabled drug discovery and development company. The Company is actively engaged in expanding its therapeutic pipeline using a proprietary artificial intelligence (AI) drug discovery and development platform, known as Algorae Operating System (AlgoraeOS). The AI platform leverages extensive medical and scientific databases from various disciplines within an advanced system at the intersection of AI and pharmaceutical research. By employing machine learning, deep learning, and neural networks, the AlgoraeOS is focused on uncovering synergistic fixed dose drug combinations that lead to the development of effective treatments for any medical condition. It is also focused on advancing its drug candidates, which include AI-116 for the treatment of neurodegenerative disorders and/or dementia, and AI-168 for cardiovascular disease and NTCELL for Parkinson’s disease.More

Announcements

Filter Results

All Price Sensitive Only

1AI	Change in substantial holding		14/10/14	95.95KB	Share
1AI	Cleansing Statement		10/10/14	13.9KB	Share
1AI	LCT JV secures funds to realise the potential of DIABECELL	PRICE SENSITIVE	10/10/14	62.18KB	Share
1AI	Appendix 3B		08/10/14	383.15KB	Share
1AI	Completion of $3m placement and SPP announced	PRICE SENSITIVE	08/10/14	279.03KB	Share
1AI	LCT collaborates to develop novel neurological treatments		29/09/14	35.62KB	Share
1AI	LCT Appoints Scientific Advisors		23/09/14	17KB	Share
1AI	2014 Annual General Meeting and Director Nominations		16/09/14	48.29KB	Share
1AI	Successful second implant of NTCELL for Parkinson's	PRICE SENSITIVE	18/08/14	48.63KB	Share
1AI	Preliminary Final Report 30 June 2014		15/08/14	311.17KB	Share
1AI	Appendix 4E and Financial Statements	PRICE SENSITIVE	15/08/14	481.12KB	Share
1AI	Change of Director's Interest Notice		01/08/14	34.23KB	Share
1AI	Appendix 4C Announcement		30/07/14	48.42KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/14	51.17KB	Share
1AI	Chief Executive's Remuneration		08/07/14	47.83KB	Share
1AI	Dr Ken Taylor appointed Chief Executive	PRICE SENSITIVE	08/07/14	66.12KB	Share
1AI	Change of Director's Interest Notice		25/06/14	22.01KB	Share
1AI	LCT Parkinson's trial resumes patient recruitment	PRICE SENSITIVE	23/06/14	62KB	Share
1AI	LCT to develop NTCELL independently	PRICE SENSITIVE	15/05/14	61.96KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/14	101.25KB	Share
1AI	Final Director's Interest Notice		01/04/14	25.88KB	Share
1AI	LCT restructures	PRICE SENSITIVE	01/04/14	273.88KB	Share
1AI	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	25/02/14	313.69KB	Share
1AI	Statement on NTCELL Phase 1 Clinical Trial		20/02/14	71.12KB	Share
1AI	Appointment of NTCELL Program Director		06/02/14	92.08KB	Share
1AI	Appendix 4C Cash Flow Report 31 December 2013		29/01/14	48.7KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/14	51.26KB	Share
1AI	Change in substantial holding		23/01/14	294.87KB	Share
1AI	Executive change		21/01/14	60.74KB	Share
1AI	Withdrawal of NTCELL pre-clinical study	PRICE SENSITIVE	19/12/13	276.5KB	Share
1AI	Change of Director's Interest Notice		16/12/13	70.29KB	Share
1AI	Change of Director's Interest Notice		16/12/13	69.95KB	Share
1AI	Change in substantial holding		09/12/13	290.72KB	Share
1AI	Response to ASX Aware Query	PRICE SENSITIVE	04/12/13	155.84KB	Share
1AI	NTCELL clinical trial - Further patients approved	PRICE SENSITIVE	25/11/13	94.64KB	Share
1AI	Results of Annual General Meeting		19/11/13	25.19KB	Share
1AI	Managing Director's Presentation to AGM		19/11/13	1.73MB	Share
1AI	Chairman's Address to Shareholders		19/11/13	149.37KB	Share
1AI	Saftey and efficacy findings of DIA 09 study of DIABECELL	PRICE SENSITIVE	01/11/13	291.91KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/13	493.4KB	Share
1AI	Australia Biotech Invest 2013		28/10/13	1.42MB	Share
1AI	Annual Report to shareholders		15/10/13	3.68MB	Share
1AI	Notice of Annual General Meeting/Proxy Form		15/10/13	96.2KB	Share
1AI	First patient successfully implanted with NTCELL	PRICE SENSITIVE	20/09/13	148.65KB	Share
1AI	Publication of pre-clinical trial of NTCELL in Parkinson's	PRICE SENSITIVE	16/09/13	27.62KB	Share
1AI	Appendix 4E and Financial Statements	PRICE SENSITIVE	30/08/13	648.48KB	Share
1AI	LCT Announces Change in Regulatory Strategy		29/08/13	34.2KB	Share
1AI	Preliminary Internal Review of Dia12 Study	PRICE SENSITIVE	27/08/13	59.15KB	Share
1AI	Change of Director's Interest Notice		01/08/13	68.56KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/13	114.03KB	Share
1AI	Change of Share Registry		08/07/13	27.91KB	Share
1AI	Change of Director's Interest Notice		29/05/13	69.91KB	Share
1AI	Open Briefing LCT Clinical Trials Update		09/05/13	153.52KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/13	118.77KB	Share
1AI	CEO on Strategy - Audio Interview		21/03/13	98.84KB	Share
1AI	Open Briefing - CEO on Strategy		21/03/13	274.96KB	Share
1AI	Living Cell Technologies Awarded NZBIO Company of the Year		20/03/13	171.27KB	Share
1AI	Announcement on Half-Year Report		27/02/13	28.51KB	Share
1AI	Appendix 4D and Half-Year Accounts	PRICE SENSITIVE	27/02/13	223.86KB	Share
1AI	Change of Director's Interest Notice		12/02/13	68.61KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/13	66.79KB	Share
1AI	Change of Director's Interest Notice		24/01/13	33.32KB	Share
1AI	Open Briefing interview with MD and CEO Andrea Grant		17/12/12	238.76KB	Share
1AI	LCT & Otsuka to co-develop NTCELL for Parkinson's Disease	PRICE SENSITIVE	17/12/12	119.44KB	Share
1AI	LCT appoints Chief Science and Medical Officer		10/12/12	46.6KB	Share
1AI	LCT starts DIABECELL Phase IIb trial in Argentina		22/11/12	44.04KB	Share
1AI	Strong interim results in Argentinian DIABECELL trial	PRICE SENSITIVE	22/11/12	50.37KB	Share
1AI	Alteration to issued capital		20/11/12	76.79KB	Share
1AI	Initial Director's Interest Notice		19/11/12	28.43KB	Share
1AI	Results of 2012 Annual General Meeting		16/11/12	27.38KB	Share
1AI	AGM Presentation		16/11/12	822.76KB	Share
1AI	Chairman's Address to the 2012 Annual General Meeting		16/11/12	39.99KB	Share
1AI	LCT CEO Dr Andrea Grant appointed Managing Director	PRICE SENSITIVE	16/11/12	41.42KB	Share
1AI	Ethical approval for LCT's NTCELL Phase I trial	PRICE SENSITIVE	16/11/12	40.08KB	Share
1AI	Change of Director's Interest Notice		05/11/12	68.68KB	Share
1AI	Six reasons to invest in LCT		02/11/12	3.88MB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/12	98.21KB	Share
1AI	Annual Report to shareholders		15/10/12	3.11MB	Share
1AI	Notice of Annual General Meeting/Proxy Form		15/10/12	91.73KB	Share
1AI	Authorisation of Ph1 trial of NTCell in Parkinsons Disease	PRICE SENSITIVE	04/10/12	25.74KB	Share
1AI	Form 492		03/10/12	82.16KB	Share
1AI	Change of Director's Interest Notice		28/09/12	68.57KB	Share
1AI	LCT announces positive DIABECELL Phase I/IIa trial	PRICE SENSITIVE	26/09/12	1.83MB	Share
1AI	Preliminary Final Report for the year ended 30 June 2012	PRICE SENSITIVE	29/08/12	758.29KB	Share
1AI	Change of Director's Interest Notice		17/08/12	68.71KB	Share
1AI	Change of Director's Interest Notice		06/08/12	67.23KB	Share
1AI	Change of Director's Interest Notice		24/07/12	68.59KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	23/07/12	100.63KB	Share
1AI	Change of Director's Interest Notice		06/06/12	67.04KB	Share
1AI	LCT restructures for next stage of growth		01/06/12	202.53KB	Share
1AI	LCT's DIABECELL trial extension approved	PRICE SENSITIVE	17/05/12	42.18KB	Share
1AI	Change of Director's Interest Notice		04/05/12	67.68KB	Share
1AI	Cleansing Statement		03/05/12	20.22KB	Share
1AI	Appendix 3B		03/05/12	68.75KB	Share
1AI	LCT's Share Purchase Plan successful		01/05/12	25.85KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/12	56.65KB	Share
1AI	Dr Barry Snow to lead Parkinson's trial for LCT		17/04/12	32.69KB	Share
1AI	Share Purchase Plan documents mailed to Shareholders		30/03/12	119.8KB	Share
1AI	LCT Presents Novel Parkinson's Disease Treatment Results	PRICE SENSITIVE	21/03/12	27.76KB	Share
1AI	LCT announces Share Purchase Plan	PRICE SENSITIVE	20/03/12	30.32KB	Share

1AI Change in substantial holding
14/10/14		95.95KB	Share
1AI Cleansing Statement
10/10/14		13.9KB	Share
1AI LCT JV secures funds to realise the potential of DIABECELL
10/10/14	PRICE SENSITIVE	62.18KB	Share
1AI Appendix 3B
08/10/14		383.15KB	Share
1AI Completion of $3m placement and SPP announced
08/10/14	PRICE SENSITIVE	279.03KB	Share
1AI LCT collaborates to develop novel neurological treatments
29/09/14		35.62KB	Share
1AI LCT Appoints Scientific Advisors
23/09/14		17KB	Share
1AI 2014 Annual General Meeting and Director Nominations
16/09/14		48.29KB	Share
1AI Successful second implant of NTCELL for Parkinson's
18/08/14	PRICE SENSITIVE	48.63KB	Share
1AI Preliminary Final Report 30 June 2014
15/08/14		311.17KB	Share
1AI Appendix 4E and Financial Statements
15/08/14	PRICE SENSITIVE	481.12KB	Share
1AI Change of Director's Interest Notice
01/08/14		34.23KB	Share
1AI Appendix 4C Announcement
30/07/14		48.42KB	Share
1AI Appendix 4C - quarterly
30/07/14	PRICE SENSITIVE	51.17KB	Share
1AI Chief Executive's Remuneration
08/07/14		47.83KB	Share
1AI Dr Ken Taylor appointed Chief Executive
08/07/14	PRICE SENSITIVE	66.12KB	Share
1AI Change of Director's Interest Notice
25/06/14		22.01KB	Share
1AI LCT Parkinson's trial resumes patient recruitment
23/06/14	PRICE SENSITIVE	62KB	Share
1AILCT to develop NTCELL independently
15/05/14	PRICE SENSITIVE	61.96KB	Share
1AIAppendix 4C - quarterly
29/04/14	PRICE SENSITIVE	101.25KB	Share
1AIFinal Director's Interest Notice
01/04/14		25.88KB	Share
1AILCT restructures
01/04/14	PRICE SENSITIVE	273.88KB	Share
1AIAppendix 4D and Half Year Financial Report
25/02/14	PRICE SENSITIVE	313.69KB	Share
1AIStatement on NTCELL Phase 1 Clinical Trial
20/02/14		71.12KB	Share
1AIAppointment of NTCELL Program Director
06/02/14		92.08KB	Share
1AIAppendix 4C Cash Flow Report 31 December 2013
29/01/14		48.7KB	Share
1AIAppendix 4C - quarterly
29/01/14	PRICE SENSITIVE	51.26KB	Share
1AIChange in substantial holding
23/01/14		294.87KB	Share
1AIExecutive change
21/01/14		60.74KB	Share
1AIWithdrawal of NTCELL pre-clinical study
19/12/13	PRICE SENSITIVE	276.5KB	Share
1AIChange of Director's Interest Notice
16/12/13		70.29KB	Share
1AIChange of Director's Interest Notice
16/12/13		69.95KB	Share
1AIChange in substantial holding
09/12/13		290.72KB	Share
1AIResponse to ASX Aware Query
04/12/13	PRICE SENSITIVE	155.84KB	Share
1AINTCELL clinical trial - Further patients approved
25/11/13	PRICE SENSITIVE	94.64KB	Share
1AIResults of Annual General Meeting
19/11/13		25.19KB	Share
1AIManaging Director's Presentation to AGM
19/11/13		1.73MB	Share
1AIChairman's Address to Shareholders
19/11/13		149.37KB	Share
1AISaftey and efficacy findings of DIA 09 study of DIABECELL
01/11/13	PRICE SENSITIVE	291.91KB	Share
1AIAppendix 4C - quarterly
30/10/13	PRICE SENSITIVE	493.4KB	Share
1AIAustralia Biotech Invest 2013
28/10/13		1.42MB	Share
1AIAnnual Report to shareholders
15/10/13		3.68MB	Share
1AINotice of Annual General Meeting/Proxy Form
15/10/13		96.2KB	Share
1AIFirst patient successfully implanted with NTCELL
20/09/13	PRICE SENSITIVE	148.65KB	Share
1AIPublication of pre-clinical trial of NTCELL in Parkinson's
16/09/13	PRICE SENSITIVE	27.62KB	Share
1AIAppendix 4E and Financial Statements
30/08/13	PRICE SENSITIVE	648.48KB	Share
1AILCT Announces Change in Regulatory Strategy
29/08/13		34.2KB	Share
1AIPreliminary Internal Review of Dia12 Study
27/08/13	PRICE SENSITIVE	59.15KB	Share
1AIChange of Director's Interest Notice
01/08/13		68.56KB	Share
1AIAppendix 4C - quarterly
31/07/13	PRICE SENSITIVE	114.03KB	Share
1AIChange of Share Registry
08/07/13		27.91KB	Share
1AIChange of Director's Interest Notice
29/05/13		69.91KB	Share
1AIOpen Briefing LCT Clinical Trials Update
09/05/13		153.52KB	Share
1AIAppendix 4C - quarterly
29/04/13	PRICE SENSITIVE	118.77KB	Share
1AICEO on Strategy - Audio Interview
21/03/13		98.84KB	Share
1AIOpen Briefing - CEO on Strategy
21/03/13		274.96KB	Share
1AILiving Cell Technologies Awarded NZBIO Company of the Year
20/03/13		171.27KB	Share
1AIAnnouncement on Half-Year Report
27/02/13		28.51KB	Share
1AIAppendix 4D and Half-Year Accounts
27/02/13	PRICE SENSITIVE	223.86KB	Share
1AIChange of Director's Interest Notice
12/02/13		68.61KB	Share
1AIAppendix 4C - quarterly
30/01/13	PRICE SENSITIVE	66.79KB	Share
1AIChange of Director's Interest Notice
24/01/13		33.32KB	Share
1AIOpen Briefing interview with MD and CEO Andrea Grant
17/12/12		238.76KB	Share
1AILCT & Otsuka to co-develop NTCELL for Parkinson's Disease
17/12/12	PRICE SENSITIVE	119.44KB	Share
1AILCT appoints Chief Science and Medical Officer
10/12/12		46.6KB	Share
1AILCT starts DIABECELL Phase IIb trial in Argentina
22/11/12		44.04KB	Share
1AIStrong interim results in Argentinian DIABECELL trial
22/11/12	PRICE SENSITIVE	50.37KB	Share
1AIAlteration to issued capital
20/11/12		76.79KB	Share
1AIInitial Director's Interest Notice
19/11/12		28.43KB	Share
1AIResults of 2012 Annual General Meeting
16/11/12		27.38KB	Share
1AIAGM Presentation
16/11/12		822.76KB	Share
1AIChairman's Address to the 2012 Annual General Meeting
16/11/12		39.99KB	Share
1AILCT CEO Dr Andrea Grant appointed Managing Director
16/11/12	PRICE SENSITIVE	41.42KB	Share
1AIEthical approval for LCT's NTCELL Phase I trial
16/11/12	PRICE SENSITIVE	40.08KB	Share
1AIChange of Director's Interest Notice
05/11/12		68.68KB	Share
1AISix reasons to invest in LCT
02/11/12		3.88MB	Share
1AIAppendix 4C - quarterly
30/10/12	PRICE SENSITIVE	98.21KB	Share
1AIAnnual Report to shareholders
15/10/12		3.11MB	Share
1AINotice of Annual General Meeting/Proxy Form
15/10/12		91.73KB	Share
1AIAuthorisation of Ph1 trial of NTCell in Parkinsons Disease
04/10/12	PRICE SENSITIVE	25.74KB	Share
1AIForm 492
03/10/12		82.16KB	Share
1AIChange of Director's Interest Notice
28/09/12		68.57KB	Share
1AILCT announces positive DIABECELL Phase I/IIa trial
26/09/12	PRICE SENSITIVE	1.83MB	Share
1AIPreliminary Final Report for the year ended 30 June 2012
29/08/12	PRICE SENSITIVE	758.29KB	Share
1AIChange of Director's Interest Notice
17/08/12		68.71KB	Share
1AIChange of Director's Interest Notice
06/08/12		67.23KB	Share
1AIChange of Director's Interest Notice
24/07/12		68.59KB	Share
1AIAppendix 4C - quarterly
23/07/12	PRICE SENSITIVE	100.63KB	Share
1AIChange of Director's Interest Notice
06/06/12		67.04KB	Share
1AILCT restructures for next stage of growth
01/06/12		202.53KB	Share
1AILCT's DIABECELL trial extension approved
17/05/12	PRICE SENSITIVE	42.18KB	Share
1AIChange of Director's Interest Notice
04/05/12		67.68KB	Share
1AICleansing Statement
03/05/12		20.22KB	Share
1AIAppendix 3B
03/05/12		68.75KB	Share
1AILCT's Share Purchase Plan successful
01/05/12		25.85KB	Share
1AIAppendix 4C - quarterly
30/04/12	PRICE SENSITIVE	56.65KB	Share
1AIDr Barry Snow to lead Parkinson's trial for LCT
17/04/12		32.69KB	Share
1AIShare Purchase Plan documents mailed to Shareholders
30/03/12		119.8KB	Share
1AILCT Presents Novel Parkinson's Disease Treatment Results
21/03/12	PRICE SENSITIVE	27.76KB	Share
1AILCT announces Share Purchase Plan
20/03/12	PRICE SENSITIVE	30.32KB	Share

REFRESH

First 4 5 6 7 8

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.7¢		Change 0.001(16.7%)		Mkt cap ! $10.12M

Open	High	Low	Value	Volume
0.6¢	0.7¢	0.6¢	$82.95K	12.56M

Buyers (Bids)

No.	Vol.	Price($)
7	3766500	0.6¢

Sellers (Offers)

Price($)	Vol.	No.
0.7¢	1627057	2

View Market Depth

No.	Vol.	Price($)
7	3766500	0.006
15	13056669	0.005
14	13997208	0.004
6	7530302	0.003
4	3900009	0.002

Price($)	Vol.	No.
0.007	1627057	2
0.008	1207573	5
0.009	142857	1
0.010	4632439	5
0.011	2498004	3

Last trade - 15.59pm 11/08/2025 (20 minute delay)


Last 0.7¢		Change 0.001 ( 16.7 %)
Open	High	Low	Volume
0.6¢	0.7¢	0.6¢	4035930
Last updated 15.59pm 11/08/2025 ?

1AI (ASX) Chart

ALGORAE PHARMACEUTICALS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories